JPH0129797B2 - - Google Patents
Info
- Publication number
- JPH0129797B2 JPH0129797B2 JP1405780A JP1405780A JPH0129797B2 JP H0129797 B2 JPH0129797 B2 JP H0129797B2 JP 1405780 A JP1405780 A JP 1405780A JP 1405780 A JP1405780 A JP 1405780A JP H0129797 B2 JPH0129797 B2 JP H0129797B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- compound
- methyl
- acetamide
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000001875 compounds Chemical class 0.000 claims description 19
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 claims description 4
- 229930186147 Cephalosporin Natural products 0.000 claims description 3
- 229940124587 cephalosporin Drugs 0.000 claims description 3
- 150000001780 cephalosporins Chemical class 0.000 claims description 3
- 125000004423 acyloxy group Chemical group 0.000 claims description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims 2
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims 1
- -1 amidinoureido group Chemical group 0.000 description 21
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 239000000243 solution Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 230000000844 anti-bacterial effect Effects 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 6
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000000921 elemental analysis Methods 0.000 description 6
- 238000002329 infrared spectrum Methods 0.000 description 6
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- SIOVKLKJSOKLIF-HJWRWDBZSA-N trimethylsilyl (1z)-n-trimethylsilylethanimidate Chemical compound C[Si](C)(C)OC(/C)=N\[Si](C)(C)C SIOVKLKJSOKLIF-HJWRWDBZSA-N 0.000 description 4
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229940126062 Compound A Drugs 0.000 description 3
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 229920001429 chelating resin Polymers 0.000 description 3
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- SJHPCNCNNSSLPL-CSKARUKUSA-N (4e)-4-(ethoxymethylidene)-2-phenyl-1,3-oxazol-5-one Chemical compound O1C(=O)C(=C/OCC)\N=C1C1=CC=CC=C1 SJHPCNCNNSSLPL-CSKARUKUSA-N 0.000 description 2
- ZVDRVTUQPJZIIY-UHFFFAOYSA-N 3h-1,3-oxazol-2-one;hydrochloride Chemical compound Cl.O=C1NC=CO1 ZVDRVTUQPJZIIY-UHFFFAOYSA-N 0.000 description 2
- 108010016626 Dipeptides Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 150000003536 tetrazoles Chemical class 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- IKWLIQXIPRUIDU-ZCFIWIBFSA-N (6r)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound OC(=O)C1=CCS[C@@H]2CC(=O)N12 IKWLIQXIPRUIDU-ZCFIWIBFSA-N 0.000 description 1
- RAIPHJJURHTUIC-UHFFFAOYSA-N 1,3-thiazol-2-amine Chemical group NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 description 1
- DXMYSJMNQVJENY-UHFFFAOYSA-N 2-[(2-amino-1,3-thiazol-4-yl)amino]acetic acid Chemical compound NC1=NC(NCC(O)=O)=CS1 DXMYSJMNQVJENY-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- 239000005973 Carvone Substances 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 241000588697 Enterobacter cloacae Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000588767 Proteus vulgaris Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- SIOVKLKJSOKLIF-UHFFFAOYSA-N bis(trimethylsilyl)acetamide Chemical compound C[Si](C)(C)OC(C)=N[Si](C)(C)C SIOVKLKJSOKLIF-UHFFFAOYSA-N 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 1
- 229960001139 cefazolin Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- LUSWEUMSEVLFEQ-UWTATZPHSA-N n-carbamoyl-alanine Chemical compound OC(=O)[C@@H](C)NC(N)=O LUSWEUMSEVLFEQ-UWTATZPHSA-N 0.000 description 1
- BSCHIACBONPEOB-UHFFFAOYSA-N oxolane;hydrate Chemical compound O.C1CCOC1 BSCHIACBONPEOB-UHFFFAOYSA-N 0.000 description 1
- RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229940007042 proteus vulgaris Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 125000004299 tetrazol-5-yl group Chemical group [H]N1N=NC(*)=N1 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 238000006227 trimethylsilylation reaction Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002132 β-lactam antibiotic Substances 0.000 description 1
- 229940124586 β-lactam antibiotics Drugs 0.000 description 1
Landscapes
- Cephalosporin Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
本発明は新規なセフアロスポリン誘導体に関す
るものである。従来よりセフエム誘導体は抗菌剤
として種々のものが開発されており、セフエム骨
格の7位アミノ基にジペプチドを結合させた誘導
体が強い抗菌活性を示すことが見出されたが、本
発明者はこのジペプチドの末端アミノ酸のアミノ
基をウイルド基またはアミジノウレイド基に変換
させることにより、より強い抗菌活性を有する化
合物が得られることを見出し本発明を完成した。
本発明の化合物は次の一般式()で表わされ
る。
式中R1はHまたはアミジノ基を意味し、R2は
Hまたは低級アルキル基を意味し、R3はアシル
オキシ基、または低級アルキル基、カルボキシメ
チル基もしくは置換アミノ低級アルキル基が置換
することもあるテトラゾールチオ基もしくはトリ
アゾールチオ基を意味し、nは0または1〜3の
整数を意味する。
本発明の化合物()を製するには種々の方法
が考えられるが、例えば式
で表わされる7β−〔2−アミノ−(2−アミノチ
アゾール−4−イル)−アセトアミド〕−3−複素
環チオメチル(ないしはアセトキシメチル)−3
−セフエム−4−カルボン酸にウレイド基または
アミジノウレイド基で置換された酢酸またはプロ
ピオン酸等をそのままないしは塩酸塩としてチオ
ニルクロリドまたは五塩化リンを作用させ、オキ
サゾロンまたは酸クロリドとして脱酸剤の存在下
に反応させればよい。それぞれの例をもつて述べ
ればD−2−ウレイドプロピオン酸を文献(ザ・
ジヤーナル・オブ・アンチバイオテイクス546、
31 1978)記載の方法によりジクロルメタン中五
塩化リンを作用させてD−2−アミノ−4−メチ
ル−5(4H)−オキサゾロン塩酸塩とする。また、
8−アミジノ−1−ウレイド酢酸をジクロルメタ
ン中塩酸ガスを吹込んで塩酸塩とした後五塩化リ
ンを作用して酸クロリドとする(特開和51−
26841公報)。このようにして得られたオキサゾロ
ンまたは酸クロリドを、アセトニトリル中室温で
N,O−ビス(トリメチルシリル)アセトアミド
を加えてトリメチルシリル化した()の反応液
の中に、脱酸剤としてプロピレンオキサイドまた
はトリエチルアミンの如き塩基を加えて、氷冷下
条件で加えて0.5〜2時間反応し、次いで室温で
5分〜1時間反応した後含水溶媒例えば水−テト
ラヒドロフランを加えてトリメチルシリル基を脱
離せしめた後溶媒を留去する。濃縮残渣にアルコ
ールの如き溶媒を加えて粗結晶を析出せしめた後
単離するかまたは濃縮残渣をそのまま適当な樹
脂、例えばダイヤイオンHP−20、ダイヤイオン
HP−10、アンバーライトXAD−などを用いた
カラムクロマトグラフイーで分離精製すれば目的
化合物を得ることができる。
かくして製される本発明のセフアロスポリン誘
導体は2−アミノチアゾール基が結合する炭素原
子およびR2が結合している炭素原子が不斉炭素
原子となることがあるから数種類の光学活性体が
生じうる。これらの光学活性体は適当な光学活性
の原料を用いて製造する方法で得るのが便利であ
り、効果の面から一般にD体を使用することが好
ましい。また、2−アミノチアゾール−4−イル
グリシンはラセミ体を使用しても良いが、効果の
面から光学活性体特にD体が好ましいと考えられ
る。
本発明化合物は広い抗菌スペクトルを有し、高
い抗菌活性を示すが、特に従来のセフエム系化合
物に耐性を示すプロテウス・ブルガリス、エンテ
ロバクター・クロアカエ、エンテロバクター・エ
ロゲネス、セラチア・マルセツセンスに強い抗菌
活性を呈し、また、シユードモナス・エルギノー
ザなど常用β−ラクタム抗生物質に高度の耐性を
示すブドウ糖非酸酵性グラム陰性桿菌およびスト
レプトコツカス・フエカーリスにも抗菌活性を示
す特徴を有している。
次に本発明の化合物を例示し、そのうち化合物
Aおよび化合物Bの抗菌力を公知の代表的セフエ
ム系化合物セフアゾリンと比較して最小発育阻止
濃度(MICμg/ml:菌量106/ml)で次表に示
す。
化合物A:7β−〔DL−2−(3−アミジノ−1−
ウレイドアセトアミド)−2−(2−アミノチア
ゾール−4−イル)アセトアミド〕−3−(1−
メチル−1H−テトラゾール−5−イル)チオ
メチル−3−セフエム−4−カルボン酸〔()
式中、R1=アミジノ、R2=H、R3=(1−メチ
ル−1H−テトラゾール−5−イル)チオ、n
=0〕
化合物B:7β−〔DL−2−(β−3−アミジノ−
1−ウレイドプロピオンアミド)−2−(2−ア
ミノチアゾール−4−イル)アセトアミド〕−
3−(1−メチル−1H−テトラゾール−5−イ
ル)チオメチル−3−セフエム−4−カルボン
酸〔()式中、R1=アミジノ、R2=H、R3=
(1−メチル−1H−テトラゾール−5−イル)
チオ、n=1〕
化合物C:7β−〔DL−2−(D−2−ウレイドプ
ロピオンアミド)−2−(2−アミノチアゾール
−4−イル)アセトアミド〕−3−(1−メチル
−1H−テトラゾール−5−イル)チオメチル
−3−セフエム−4−カルボン酸〔()式中、
R1=H、R2=メチル、R3=(1−メチル−1H
−テトラゾール−5−イル)チオ、n=0〕
化合物D:7β−〔DL−2−(D−2−ウレイドプ
ロピオンアミド)−2−(2−アミノチアゾール
−4−イル)アセトアミド〕−3−〔1−(2−
ジメチルアミノエチル)−1H−テトラゾール−
5−イル〕チオメチル−3−セフエム−4−カ
ルボン酸〔()式中、R1=H、R2=メチル、
R3=(1−(2−ジメチルアミノエチル)−1H
−テトラゾール−5−イル〕チオ、n=0〕
化合物E:7β−〔DL−2−(D−2−ウレイドプ
ロピオンアミド)−2−(2−アミノチアゾール
−4−イル)アセトアミド〕−3−(5−カルボ
キシメチル−1H−1,2,4−トリアゾール
−3−イル〕チオメチル−3−セフエム−4−
カルボン酸〔()式中、R1=H、R2=メチ
ル、R3=(5−カルボキシメチル−1H−1,
2,4−トリアゾール−3−イル)チオ、n=
0〕
化合物F:7β−〔DL−2−(D−2−ウレイドプ
ロピオンアミド)−2−(2−アミノチアゾール
−4−イル)アセトアミド〕−3−アセトキシ
メチル−3−セフエム−4−カルボン酸〔()
式中、R1=H、R2=メチル、R3=アセトキシ、
n=0〕
The present invention relates to novel cephalosporin derivatives. Various Cefem derivatives have been developed as antibacterial agents, and it was discovered that a derivative with a dipeptide bonded to the 7-position amino group of the Cefem skeleton exhibits strong antibacterial activity. We have completed the present invention by discovering that a compound with stronger antibacterial activity can be obtained by converting the amino group of the terminal amino acid of a dipeptide into a wild group or an amidinoureido group. The compound of the present invention is represented by the following general formula (). In the formula, R 1 means H or an amidino group, R 2 means H or a lower alkyl group, and R 3 may be substituted with an acyloxy group, or a lower alkyl group, a carboxymethyl group, or a substituted amino lower alkyl group. It means a certain tetrazolethio group or triazolethio group, and n means 0 or an integer from 1 to 3. Various methods can be considered for producing the compound () of the present invention, for example, the formula 7β-[2-amino-(2-aminothiazol-4-yl)-acetamido]-3-heterocyclic thiomethyl (or acetoxymethyl)-3 represented by
- Cefem-4-carboxylic acid is substituted with a ureido group or amidinoureido group, such as acetic acid or propionic acid, either as it is or as a hydrochloride, and treated with thionyl chloride or phosphorus pentachloride, and converted into oxazolone or acid chloride in the presence of a deoxidizing agent. All you have to do is react. To give an example of each, D-2-ureidopropionic acid is described in the literature (the
Journal of Antibiotics 546,
D-2-amino-4-methyl-5(4H)-oxazolone hydrochloride is obtained by reacting with phosphorus pentachloride in dichloromethane according to the method described in 1978). Also,
8-Amidino-1-ureidoacetic acid is converted into a hydrochloride salt by blowing hydrochloric acid gas into dichloromethane, and then treated with phosphorus pentachloride to form an acid chloride (JP-A-51-
26841 Publication). The oxazolone or acid chloride thus obtained was trimethylsilylated by adding N,O-bis(trimethylsilyl)acetamide in acetonitrile at room temperature. Propylene oxide or triethylamine was added as a deoxidizing agent to the reaction solution (2). Add a base such as the following and react for 0.5 to 2 hours under ice-cooling conditions. Then, after reacting for 5 minutes to 1 hour at room temperature, add a water-containing solvent such as water-tetrahydrofuran to remove the trimethylsilyl group, and then remove the solvent. To leave. A solvent such as alcohol is added to the concentrated residue to precipitate crude crystals, which are then isolated, or the concentrated residue is directly mixed with a suitable resin such as Diaion HP-20, Diaion
The target compound can be obtained by separating and purifying it by column chromatography using HP-10, Amberlite XAD-, etc. In the thus produced cephalosporin derivative of the present invention, the carbon atom to which the 2-aminothiazole group is bonded and the carbon atom to which R 2 is bonded may be asymmetric carbon atoms, and therefore several types of optically active forms may be produced. It is convenient to obtain these optically active forms by a manufacturing method using suitable optically active raw materials, and it is generally preferable to use the D form from the viewpoint of effectiveness. Furthermore, although a racemic form of 2-aminothiazol-4-ylglycine may be used, an optically active form, particularly a D form, is considered preferable from the viewpoint of effectiveness. The compound of the present invention has a broad antibacterial spectrum and exhibits high antibacterial activity, but has particularly strong antibacterial activity against Proteus vulgaris, Enterobacter cloacae, Enterobacter erogenes, and Serratia marsetuscens, which are resistant to conventional cefem compounds. It also exhibits antibacterial activity against glucose non-acid-fermenting Gram-negative bacilli, such as Pseudomonas aeruginosa, which are highly resistant to commonly used β-lactam antibiotics, and Streptococcus fuecalis. Next, the compounds of the present invention will be illustrated, and the antibacterial activity of Compound A and Compound B will be compared with that of cefazolin, a known representative cefem compound, and the following results will be shown in terms of minimum inhibitory concentration (MIC μg/ml: bacterial mass 10 6 /ml). Shown in the table. Compound A: 7β-[DL-2-(3-amidino-1-
ureidoacetamide)-2-(2-aminothiazol-4-yl)acetamide]-3-(1-
Methyl-1H-tetrazol-5-yl)thiomethyl-3-cephem-4-carboxylic acid [()
In the formula, R 1 = amidino, R 2 = H, R 3 = (1-methyl-1H-tetrazol-5-yl)thio, n
=0] Compound B: 7β-[DL-2-(β-3-amidino-
1-ureidopropionamide)-2-(2-aminothiazol-4-yl)acetamide]-
3-(1-methyl-1H-tetrazol-5-yl)thiomethyl-3-cephem-4-carboxylic acid [(in the formula, R 1 = amidino, R 2 = H, R 3 =
(1-methyl-1H-tetrazol-5-yl)
thio, n=1] Compound C: 7β-[DL-2-(D-2-ureidopropionamide)-2-(2-aminothiazol-4-yl)acetamide]-3-(1-methyl-1H- Tetrazol-5-yl)thiomethyl-3-cephem-4-carboxylic acid [() in the formula,
R 1 = H, R 2 = methyl, R 3 = (1-methyl-1H
-tetrazol-5-yl)thio, n=0] Compound D: 7β-[DL-2-(D-2-ureidopropionamide)-2-(2-aminothiazol-4-yl)acetamide]-3- [1-(2-
dimethylaminoethyl)-1H-tetrazole-
5-yl]thiomethyl-3-cephem-4-carboxylic acid [() in the formula, R 1 = H, R 2 = methyl,
R 3 = (1-(2-dimethylaminoethyl)-1H
-tetrazol-5-yl]thio, n=0] Compound E: 7β-[DL-2-(D-2-ureidopropionamide)-2-(2-aminothiazol-4-yl)acetamide]-3- (5-carboxymethyl-1H-1,2,4-triazol-3-yl]thiomethyl-3-cephem-4-
Carboxylic acid [(in the formula, R 1 = H, R 2 = methyl, R 3 = (5-carboxymethyl-1H-1,
2,4-triazol-3-yl)thio, n=
0] Compound F: 7β-[DL-2-(D-2-ureidopropionamide)-2-(2-aminothiazol-4-yl)acetamide]-3-acetoxymethyl-3-cephem-4-carboxylic acid [()
In the formula, R 1 = H, R 2 = methyl, R 3 = acetoxy,
n=0]
【表】
実施例 1
化合物Aの製造
7β−〔DL−2−アミノ−(2−アミノチアゾー
ル−4−イル)アセトアミド〕−3−(1−メチル
−1H−テトラゾール−5−イル)チオメチル−
3−セフエム−4−カルボン酸483mgを無水アセ
トニトリル8mlに懸濁しついでこれにN,O−ビ
ス(トリメチルシリル)アセトアミドの2モルク
ロロホルム溶液2.2mlを加えてトリメチルシリル
化した後プロピレンオキサイド0.22mlを加える。
これに3−アミジノ−1−ウレイド酢酸クロリド
塩酸塩293mgを氷冷下撹拌しつつ加え、同温で1.5
時間、室温で10分撹拌する。反応液に水25ml、テ
トラヒドロフラン5mlの混合液5mlを加えて減圧
下に有機溶媒を留去する。残つた水層部をダイヤ
イオンHP−20のカラムクロマトに通して精製し
て7β〔DL−2−(3−アミジノ−1−ウレイドア
セトアミド)−2−(2−アミノチアゾール−4−
イル)アセトアミド〕−3−(1−メチル−1H−
テトラゾール−5−イル)チオメチル−3−セフ
エム−4−カルボン酸を236mg得た。
元素分析値 C19H23O6N13S3・H2Oとして
計算値 C 35.45、H 391、N 28.29
実測値 C 35.40、H3.95、N 27.99
NMRスペクトル(90MHz、D2O+Py−d5の混液
中)δppm
3.5〜4.0(2H、bro.、2−H)
4.07、4.09(3H、each s、DL体によるテトラ
ゾール1−CH3)
4.26(2H、s、ウレイドアセチル CH2)
4.45(2H、bro.s、3−CH2)
5.29、5.33(1H、each d、J=5Hz、DL体に
よる6−H)
5.82(1H、s、チアゾールグリシンCH)
5.93、6.01(1H、each d、J=5Hz、DL体に
よる7−H)
6.88、6.90(1H、each s、DL体におけるチア
ゾール5−H)
IRスペクトルνKBr nax3350、1765cm-1
実施例 2
化合物Bの製造
7β−〔DL−2−アミノ−2−(2−アミノチア
ゾール−4−イル)アセトアミド〕−3−(1−メ
チル−1H−テトラゾール−5−イル)チオメチ
ル−3−セフエム−4−カルボン酸483mgを無水
アセトニトリル8mlに懸濁し次いでこれにN,0
−ビス(トリメチルシリル)アセトアミドの2モ
ルクロロホルム溶液2.2mlを加えてトリメチルシ
リル化した後プロピレンオキサイド0.22mlを加え
る。反応液を氷冷下撹拌しつつβ−(3−アミジ
ノ−1−ウレイド)プロピオン酸クロリド塩酸塩
359mgを加えて同温で1.5時間、室温で10分間撹拌
する。反応液に水2.5ml、テトラヒドロフラン5
mlの混液5mlを加え減圧下に有機溶媒を留去し、
少量の水を加えて析出する不溶物を濾取した後水
層部をダイヤイオンHP−20のカラムクロマトに
通して精製して化合物Bを86mg得た。
元素分析値 C20H25O6N13・21/2H2Oとして
計算値 C 35.08、H 4.42、N 26.59
実測値 C 35.58、H 4.10、N 25.92
NMRスペクトル(90MHz、D2O+Py−d5の混液
中)δppm
2.95(2H、bro.s、ウレイドプロピオニル2−
CH2)
3.80(4H、bro.2−Hとウレイドプロピオニル3
−CH2)
4.10、4.12(1H、each s、DL体によるテトラ
ゾール1−CH3)
4.47(2H、bro.s、3−CH2)
5.85(1H、s、チアゾールグリシンCH)
5.96、6.03(1H、each d、J=5Hz、DL体に
よる7−H)
6.90、6.93(1H、each s、DL体によるチアゾ
ール5−H)
IRスペクトルνKBr nax3375、1765cm-1
実施例 3
化合物Cの製造
7β−〔DL−2−アミノ−2−(2−アミノチア
ゾール−4−イル)アセトアミド〕−3−(1−メ
チル−1H−テトラゾール−5−イル)チオメチ
ル−3−セフエム−4−カルボン483mgを無水ア
セトニトリル5mlに懸濁し次いでN,O−ビス
(トリメチルシリル)アセトアミドの2モルクロ
ロホルム溶液3mlを加えてトリメチルシリル化し
た後プロピレンオキサイド203mgを加える。氷冷
撹拌下D−2−アミノ−4−メチル−5(4H)−
オキサゾロン塩酸塩166mgを加える。同温にて2
時間撹拌した。水25ml−テトラヒドロフラン5ml
の混液中に投入した後減圧下に濃縮し、残つた水
層部をアンバーライトXAD−のカラムに通し
て精製して化合物C385mgを得た。
元素分析値 C19H23N11O6S3として
計算値 C 38.18、H 3.88、N 25.78
実測値 C 38.35、H 4.19、N 24.95
NMRスペクトル(90MHz、DMSO−d6)δppm
1.17(3H、d、J=7Hz、ウレイドプロピオニ
ルCH3CH)
3.67(2H、bro、s、2−H)
3.96(3H、s、テトラゾール 1−CH3)
3.9〜4.6(3H、bro.、3−CH2およびウレイド
プロピオニルCH)
5.05、5.08(1H、each d、J=5Hz、DL体に
よる6−H)
5.43(1H、d、J=8Hz、チアゾールグリシン
CH)
5.62(3H、bro.s、NH2およびCOOH)
6.15〜6.50(1H、bro、NH)
6.42、6.46(1H、each s、チアゾール5−H)
6.97(2H、bro.s、NH2)
8.15(1H、d、j=5Hz、NH)
8.9〜9.2(1H、bro、NH)
IRスペクトルνKBr nax3350、1770、1660cm-
実施例 4
化合物Dの製造
7β−〔DL−2−アミノ−2−(2−アミノチア
ゾール−4−イル)アセトアミド〕−3−〔1−
(2−ジメチルアミノエチル)−1H−テトラゾー
ル−5−イル)チオメチル−3−セフエム−4−
カルボン酸390mgを無水アセトニトリル7.5mlに懸
濁し、次いでN,O−ビス(トリメチルシリル)
アセトアミドの2モルクロロホルム溶液1.5mlを
加えてトリメチルシリル化した後プロピレンオキ
サイド0.18mlを加える。氷冷撹拌下D−2−アミ
ノ−4−メチル−5(4H)−オキサゾロン塩酸塩
106mgを加える。同温で30分、室温で2時間反応
した。水25ml、テトラヒドロフラン5mlの混合溶
媒5mlを加えた後減圧下に有機溶媒を留去し、水
2mlを加えてさらにエタノール40ml、エーテル5
mlを加えて析出する粉末を濾取。この粉末を適量
の水に溶解した後アンバーライトXAD−のカ
ラムクロマトで精製して化合物D107mgを得た。
元素分析値 C22H30O6N12S3・2H2Oとして
計算値 C 38.25、H 4.96、N 24.33
実測値 C 38.35、H 4.46、N 23.06
NMRスペクトル(90MHz、D2O)δppm
1.39(3H、d、J=7.5Hz、ウレイドプロピオニ
ルCH3CH)
3.05(6H、s、ジメチルアミノ)
3.5〜4.0(4H、2−Hおよびジメチルアミノエ
チル2−CH2)
4.1〜4.5(3H、3−CH2とウレイドプロピオニ
ルCH)
4.8〜5.0(2H、ジメチルアミノエチル1−CH2)
5.10〜5.24(1H、6−H)
5.45(1H、s、チアゾールグリシンCH)
5.58〜5.72(1H、7−H)
6.68、6.72(1H、each s、DL体によるチアゾ
ール5−H)
IRスペクトルνKBr nax3350、1770、1660cm-1
実施例 5
化合物Eの製造
7β−〔DL−2−アミノ−(2−アミノチアゾール
−4−イル)アセトアミド〕−3−(5−カルボキ
シメチル−1H−1,2,4−トリアゾール−3
−イル)チオメチル−3−セフエム−4−カルボ
ン酸263mgとD−2−アミノ−4−メチル−5
(4H)オキサゾロン塩酸塩83mgを実施例3と同様
に反応して化合物E74mgを得た。
元素分析値 C21H24O8N10S3・2H2Oとして
計算値 C 38.27、H 4.17、N 20.70
実測値 C 37.72、H 4.00、N 20.26
NMRスペクトル(90MHz、D2O+Py−d5の混液
中)δppm
1.42(3H、d、J=7Hz、ウレイドプロピオニ
ルCH3CH)
3.2〜4.0(2H、bro.、2−H)
3.76(2H、s、トリアゾール 5−CH2)
3.9〜4.5(2H、bro、3−CH2)
4.30(1H、q、J=7Hz、ウレイドプロピオニ
ルCH)
5.12、5.15(1H、d、J=4Hz、DL体による6
−H)
5.50(1H、s、チアゾールグリシンCH)
5.66、5.70(1H、d、J=4Hz、DL体による7
−H)
6.69、6.74(1H、s、DL体によるチアゾール5
−H)
IRスペクトルνKBr nax1760、1660cm-1
実施例 6
化合物Fの製造
7−β−〔DL−2−アミノ−2−(2−アミノ
チアゾール−4−イル)アセトアミド〕−3−ア
セトキシメチル−3−セフエム−4−カルボン酸
1.36gを無水アセトニトリル16mlに懸濁し、次い
でN,O−ビス(トリメチルシリル)アセトアミ
ドの2モルクロロホルム溶液5.5mlを加えてトリ
メチルシリル化した後プロピレンオキサイド0.85
mlを加える。氷冷撹拌下D−2−アミノ−4−メ
チル−5(4H)−オキサゾロン塩酸塩480mgを加え
る。同温で30分、室温で1時間反応した。水25ml
−テトラヒドロフラン5mlの混合溶媒5mlを加え
た後減圧下に有機溶媒を留去し、残り水層部にエ
タノールを加えて析出する粉末を濾取する。エー
テルでよく洗浄して化合物F320mgを得た。
元素分析値 C19H23O8N7S2・11/2として
計算値 C 40.14、H 4.61、N 17.24
実測値 C 40.76、H 4.35、N 16.70
NMRスペクトル(90MHz、D2O+Py−d5の混液
中)δppm
1.50、1.52(3H each d、J=7Hz、DL体によ
るウレイドプロピオニルCH3CH)
2.21、2.24(3H、each s、DL体によるアセチ
ルメチル)
3.4〜3.9(2H、bro、2−H)
4.3〜4.6(2H、bro、3−CH2)
5.20、5.26(1H、each d、J=5Hz、DL体に
よる6−H)
5.64(1H、s、チアゾールグリシンCH)
5.82、5.88(1H、each d、J=5Hz、DL体に
よる7−H)
6.80、6.85(1H、each s、DL体によるチアゾ
ール5−H)
IRスペクトルνKBr nax1770、1650cm-1 [Table] Example 1 Production of compound A 7β-[DL-2-amino-(2-aminothiazol-4-yl)acetamide]-3-(1-methyl-1H-tetrazol-5-yl)thiomethyl-
483 mg of 3-cephem-4-carboxylic acid is suspended in 8 ml of anhydrous acetonitrile, and 2.2 ml of a 2 molar chloroform solution of N,O-bis(trimethylsilyl)acetamide is added to trimethylsilylate, followed by the addition of 0.22 ml of propylene oxide.
To this was added 293 mg of 3-amidino-1-ureidoacetic acid chloride hydrochloride while stirring under ice cooling, and at the same temperature
Stir for 10 minutes at room temperature. 5 ml of a mixture of 25 ml of water and 5 ml of tetrahydrofuran is added to the reaction solution, and the organic solvent is distilled off under reduced pressure. The remaining aqueous layer was purified by passing it through Diaion HP-20 column chromatography to obtain 7β[DL-2-(3-amidino-1-ureidoacetamide)-2-(2-aminothiazole-4-
yl)acetamide]-3-(1-methyl-1H-
236 mg of thiomethyl-3-cephem-4-carboxylic acid (tetrazol-5-yl) was obtained. Elemental analysis value C 19 H 23 O 6 N 13 S 3・H 2 O Calculated value C 35.45, H 391, N 28.29 Actual value C 35.40, H 3.95, N 27.99 NMR spectrum (90MHz, D 2 O + Py-d 5 (in a mixed solution of , bro.s, 3-CH 2 ) 5.29, 5.33 (1H, each d, J=5Hz, 6-H with DL body) 5.82 (1H, s, thiazoleglycine CH) 5.93, 6.01 (1H, each d, J =5Hz, 7-H in DL form) 6.88, 6.90 (1H, each s, thiazole 5-H in DL form) IR spectrum ν KBr nax 3350, 1765 cm -1 Example 2 Production of compound B 7β-[DL-2 -Amino-2-(2-aminothiazol-4-yl)acetamide]-3-(1-methyl-1H-tetrazol-5-yl)thiomethyl-3-cephem-4-carboxylic acid (483 mg) was suspended in 8 ml of anhydrous acetonitrile. Cloudy and then this N,0
- Add 2.2 ml of a 2 molar chloroform solution of bis(trimethylsilyl)acetamide to trimethylsilylate it, then add 0.22 ml of propylene oxide. β-(3-amidino-1-ureido)propionic acid chloride hydrochloride was added while stirring the reaction solution under ice cooling.
Add 359 mg and stir at the same temperature for 1.5 hours and at room temperature for 10 minutes. Add 2.5 ml of water and 5 ml of tetrahydrofuran to the reaction solution.
Add 5 ml of the mixture and remove the organic solvent under reduced pressure.
After adding a small amount of water and filtering out the precipitated insoluble matter, the aqueous layer was purified by passing through a Diaion HP-20 column chromatography to obtain 86 mg of Compound B. Elemental analysis value C 20 H 25 O 6 N 13・21/2H 2 O Calculated value C 35.08, H 4.42, N 26.59 Actual value C 35.58, H 4.10, N 25.92 NMR spectrum (90MHz, D 2 O + Py-d 5 in mixed solution) δppm 2.95 (2H, bro.s, ureidopropionyl 2-
CH 2 ) 3.80 (4H, bro.2-H and ureidopropionyl 3
-CH2 ) 4.10, 4.12 (1H, each s, tetrazole by DL form 1- CH3 ) 4.47 (2H, bro.s, 3- CH2 ) 5.85 (1H, s, thiazoleglycine CH) 5.96, 6.03 (1H , each d, J=5Hz, 7-H in DL form) 6.90, 6.93 (1H, each s, thiazole 5-H in DL form) IR spectrum ν KBr nax 3375, 1765 cm -1 Example 3 Production of compound C 7β -[DL-2-amino-2-(2-aminothiazol-4-yl)acetamide]-3-(1-methyl-1H-tetrazol-5-yl)thiomethyl-3-cephem-4-carvone 483 mg anhydrous The suspension was suspended in 5 ml of acetonitrile, and then 3 ml of a 2 molar chloroform solution of N,O-bis(trimethylsilyl)acetamide was added for trimethylsilylation, followed by the addition of 203 mg of propylene oxide. D-2-amino-4-methyl-5(4H)- under ice-cooling and stirring
Add 166 mg of oxazolone hydrochloride. At the same temperature 2
Stir for hours. 25ml water - 5ml tetrahydrofuran
The mixture was concentrated under reduced pressure, and the remaining aqueous layer was purified by passing through an Amberlite XAD- column to obtain 385 mg of Compound C. Elemental analysis value C 19 H 23 N 11 O 6 S 3 Calculated value C 38.18, H 3.88, N 25.78 Actual value C 38.35, H 4.19, N 24.95 NMR spectrum (90MHz, DMSO-d 6 ) δppm 1.17 (3H, d , J=7Hz, ureidopropionyl CH3CH ) 3.67 (2H, bro, s, 2-H) 3.96 (3H, s, tetrazole 1- CH3 ) 3.9-4.6 (3H, bro., 3 -CH2 and ureido Propionyl CH) 5.05, 5.08 (1H, each d, J = 5Hz, 6-H by DL form) 5.43 (1H, d, J = 8Hz, thiazoleglycine
CH) 5.62 (3H, bro.s, NH2 and COOH) 6.15-6.50 (1H, bro, NH) 6.42, 6.46 (1H, each s, thiazole 5-H) 6.97 (2H, bro.s, NH2 ) 8.15 (1H, d, j = 5Hz, NH) 8.9-9.2 (1H, bro, NH) IR spectrum ν KBr nax 3350, 1770, 1660cm -Example 4 Production of compound D 7β-[DL-2-amino-2 -(2-aminothiazol-4-yl)acetamide]-3-[1-
(2-dimethylaminoethyl)-1H-tetrazol-5-yl)thiomethyl-3-cephem-4-
390 mg of carboxylic acid was suspended in 7.5 ml of anhydrous acetonitrile, and then N,O-bis(trimethylsilyl)
Add 1.5 ml of a 2 molar chloroform solution of acetamide to trimethylsilylate, and then add 0.18 ml of propylene oxide. D-2-amino-4-methyl-5(4H)-oxazolone hydrochloride under ice-cooling and stirring
Add 106 mg. The reaction was carried out at the same temperature for 30 minutes and at room temperature for 2 hours. After adding 5 ml of a mixed solvent of 25 ml of water and 5 ml of tetrahydrofuran, the organic solvent was distilled off under reduced pressure, and 2 ml of water was added, followed by 40 ml of ethanol and 5 ml of ether.
ml and filter out the precipitated powder. This powder was dissolved in an appropriate amount of water and purified using Amberlite XAD column chromatography to obtain 107 mg of Compound D. Elemental analysis value C 22 H 30 O 6 N 12 S 3・2H 2 O Calculated value C 38.25, H 4.96, N 24.33 Actual value C 38.35, H 4.46, N 23.06 NMR spectrum (90MHz, D 2 O) δppm 1.39 ( 3H, d, J = 7.5Hz, ureidopropionyl CH3CH ) 3.05 (6H, s, dimethylamino) 3.5-4.0 (4H, 2-H and dimethylaminoethyl 2- CH2 ) 4.1-4.5 (3H, 3- CH2 and ureidopropionyl CH) 4.8-5.0 (2H, dimethylaminoethyl 1- CH2 ) 5.10-5.24 (1H, 6-H) 5.45 (1H, s, thiazoleglycine CH) 5.58-5.72 (1H, 7-H ) 6.68, 6.72 (1H, each s, thiazole 5-H with DL form) IR spectrum ν KBr nax 3350, 1770, 1660 cm -1 Example 5 Preparation of compound E 7β-[DL-2-amino-(2-amino thiazol-4-yl)acetamide]-3-(5-carboxymethyl-1H-1,2,4-triazole-3
-yl)thiomethyl-3-cephem-4-carboxylic acid 263 mg and D-2-amino-4-methyl-5
(4H) 83 mg of oxazolone hydrochloride was reacted in the same manner as in Example 3 to obtain 74 mg of compound E. Elemental analysis value C 21 H 24 O 8 N 10 S 3・2H 2 O Calculated value C 38.27, H 4.17, N 20.70 Actual value C 37.72, H 4.00, N 20.26 NMR spectrum (90MHz, D 2 O + Py-d 5 (in mixed liquid) δppm 1.42 (3H, d, J = 7Hz, ureidopropionyl CH 3 CH) 3.2-4.0 (2H, bro., 2-H) 3.76 (2H, s, triazole 5-CH 2 ) 3.9-4.5 (2H , bro, 3-CH 2 ) 4.30 (1H, q, J = 7Hz, ureidopropionyl CH) 5.12, 5.15 (1H, d, J = 4Hz, 6 by DL form
-H) 5.50 (1H, s, thiazoleglycine CH) 5.66, 5.70 (1H, d, J = 4Hz, 7 by DL body
-H) 6.69, 6.74 (1H, s, DL form of thiazole 5
-H) IR spectrum ν KBr nax 1760, 1660 cm -1 Example 6 Preparation of compound F 7-β-[DL-2-amino-2-(2-aminothiazol-4-yl)acetamide]-3-acetoxymethyl -3-cephem-4-carboxylic acid
1.36 g was suspended in 16 ml of anhydrous acetonitrile, and then 5.5 ml of a 2 molar chloroform solution of N,O-bis(trimethylsilyl)acetamide was added to trimethylsilylate, followed by 0.85 g of propylene oxide.
Add ml. Add 480 mg of D-2-amino-4-methyl-5(4H)-oxazolone hydrochloride while stirring on ice. The reaction was carried out at the same temperature for 30 minutes and at room temperature for 1 hour. 25ml water
- After adding 5 ml of a mixed solvent of 5 ml of tetrahydrofuran, the organic solvent was distilled off under reduced pressure, ethanol was added to the remaining aqueous layer, and the precipitated powder was collected by filtration. After thorough washing with ether, 320 mg of compound F was obtained. Elemental analysis value C 19 H 23 O 8 N 7 S 2・11/2 Calculated value C 40.14, H 4.61, N 17.24 Actual value C 40.76, H 4.35, N 16.70 NMR spectrum (90MHz, D 2 O + Py-d 5 (in mixed solution) δppm 1.50, 1.52 (3H each d, J=7Hz, ureidopropionyl CH 3 CH by DL form) 2.21, 2.24 (3H, each s, acetylmethyl by DL form) 3.4-3.9 (2H, bro, 2- H) 4.3-4.6 (2H, bro, 3-CH 2 ) 5.20, 5.26 (1H, each d, J=5Hz, 6-H with DL body) 5.64 (1H, s, thiazoleglycine CH) 5.82, 5.88 (1H , each d, J=5Hz, 7-H by DL form) 6.80, 6.85 (1H, each s, thiazole 5-H by DL form) IR spectrum ν KBr nax 1770, 1650 cm -1
Claims (1)
塩。ただし、式中R1はHまたはアミジノ基を意
味し、R2はHまたは低級アルキル基を意味し、
R3はアシルオキシ基、または低級アルキル基、
カルボキシメチル基もしくは置換アミノ低級アル
キル基が置換することもあるテトラゾールチオ基
もしくはトリアゾールチオ基を意味し、nは0ま
たは1〜3の整数を意味する。 2 7β−〔DL−2−(3−アミジノ−1−ウレイ
ドアセトアミド)−2−(2−アミノチアゾール−
4−イル)アセトアミド〕−3−(1−メチル−
1H−テトラゾール−5−イル)チオメチル−3
−セフエム−4−カルボン酸またはその塩である
特許請求の範囲第1項記載の化合物。[Claims] 1 formula A cephalosporin derivative represented by or a salt thereof. However, in the formula, R 1 means H or an amidino group, R 2 means H or a lower alkyl group,
R 3 is an acyloxy group or a lower alkyl group,
It means a tetrazolethio group or a triazolethio group which may be substituted with a carboxymethyl group or a substituted amino lower alkyl group, and n means 0 or an integer of 1 to 3. 2 7β-[DL-2-(3-amidino-1-ureidoacetamide)-2-(2-aminothiazole-
4-yl)acetamido]-3-(1-methyl-
1H-tetrazol-5-yl)thiomethyl-3
-Cefem-4-carboxylic acid or a salt thereof, the compound according to claim 1.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP1405780A JPS56110691A (en) | 1980-02-07 | 1980-02-07 | Cephalosporin derivative |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP1405780A JPS56110691A (en) | 1980-02-07 | 1980-02-07 | Cephalosporin derivative |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS56110691A JPS56110691A (en) | 1981-09-01 |
JPH0129797B2 true JPH0129797B2 (en) | 1989-06-14 |
Family
ID=11850452
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP1405780A Granted JPS56110691A (en) | 1980-02-07 | 1980-02-07 | Cephalosporin derivative |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS56110691A (en) |
-
1980
- 1980-02-07 JP JP1405780A patent/JPS56110691A/en active Granted
Also Published As
Publication number | Publication date |
---|---|
JPS56110691A (en) | 1981-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4912212A (en) | Cephem compounds | |
US4203899A (en) | Thiazolylacetamido compounds | |
US4298606A (en) | Thiazolylacetamido compounds | |
US4487767A (en) | 7-[Amino or carboxy substituted oxyimino]-3-[amino or alkoxy substituted heterocyclic thiomethyl] cephalosporin derivatives | |
HU204277B (en) | Process for producing 7-(2-65-amino-1,2,4-thiadiazol-3-yl/-2-imino-acetamido/-3-(3-halogeno-1- -propen-1-yl)-ceph-3-eme-4-carboxylates | |
US4355160A (en) | Thiazolylacetamido cephalosporin type compounds | |
US4698337A (en) | Cephem compounds and processes for preparation thereof | |
CH635846A5 (en) | BROAD SPECTRUM CEPHALOSPORIN ANTIBIOTICS. | |
US4668783A (en) | Thiazolylacetamido cephalosporin compounds | |
JPS62161789A (en) | Production of cephalosporines | |
JPH0129797B2 (en) | ||
KR930007260B1 (en) | Process for preparing cephalosporin derivatives | |
US4239758A (en) | Cephalosporins | |
KR910005230B1 (en) | Process for producing azetidinones | |
JPS6337106B2 (en) | ||
JPH0121153B2 (en) | ||
JP2867438B2 (en) | Method for producing cephalosporin compounds | |
GB2039890A (en) | New cephem compounds | |
KR900003562B1 (en) | Process for preparing sillyl cephalosproin derivatives | |
HU185954B (en) | Process for preparing cephem-carboxylic acid derivatives substituted with bis-tetrazolyl-methyl group | |
KR800000546B1 (en) | Process for preparing thiazolylacet amido cephalosporins | |
KR840001616B1 (en) | Process for preparing nobel cephem compound | |
CA1103236A (en) | 3-acyloxymethyl-cephem compounds | |
JPS6210512B2 (en) | ||
JPS60120888A (en) | Cephem derivative |